Role of rho-kinase in the regulation of vascular tone in hypertensive renal transplant recipients

Atherosclerosis

Volumn 207, Issue 2, 2009, Pages 567-572

  Bussemaker E ^a   Herbrig, K ^b   Pistrosch, F ^b   Palm, C ^b   Passauer, J ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Arterial hypertension; Forearm blood flow; Kidney transplantation; Nitric oxide; Rho kinase

Indexed keywords

CYCLOSPORIN A; FASUDIL; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N(G) METHYLARGININE; NITRIC OXIDE; RHO KINASE; TACROLIMUS;

ADULT; ARTICLE; BLOOD VESSEL COMPLIANCE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FOREARM BLOOD FLOW; GRAFT RECIPIENT; HUMAN; HYPERTENSION; KIDNEY GRAFT; MALE; PRIORITY JOURNAL; VASOCONSTRICTION; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FOREARM; HUMANS; HYPERTENSION; INFUSIONS, INTRA-ARTERIAL; KIDNEY TRANSPLANTATION; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE; NOREPINEPHRINE; OMEGA-N-METHYLARGININE; PLETHYSMOGRAPHY; PROTEIN KINASE INHIBITORS; REGIONAL BLOOD FLOW; RHO-ASSOCIATED KINASES; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 70450246974     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.05.025     Document Type: Article

References (50)

1. Kasiske B.L., Anjum S., Shah R., et al. Hypertension after kidney transplantation. Am J Kidney Dis 43 (2004) 1071-1081
2. Ponticelli C., Montagnino G., Aroldi A., et al. Hypertension after renal transplantation. Am J Kidney Dis 21 (1993) 73-78
3. Fellstrom B. Risk factors for and management of post-transplantation cardiovascular disease. BioDrugs 15 (2001) 261-278
4. Campistol J.M., Romero R., Paul J., and Gutierrez-Dalmau A. Epidemiology of arterial hypertension in renal transplant patients: changes over the last decade. Nephrol Dial Transplant 19 Suppl 3 (2004) iii62-iii66
5. Diaz J.M., Sainz Z., Guirado L.L., et al. Risk factors for cardiovascular disease after renal transplantation. Transplant Proc 35 (2003) 1722-1724
6. First M.R., Neylan J.F., Rocher L.L., and Tejani A. Hypertension after renal transplantation. J Am Soc Nephrol 4 (1994) S30-S36
7. Kannel W.B. Role of blood pressure in cardiovascular disease: the Framingham study. Angiology 26 (1975) 1-14
8. Rigatto C., Foley R., Jeffery J., et al. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 14 (2003) 462-468
9. Opelz G., Wujciak T., and Ritz E. Association of chronic kidney graft failure with recipient blood pressure, collaborative transplant study. Kidney Int 53 (1998) 217-222
10. Midtvedt K., and Hartmann A. Hypertension after kidney transplantation: are treatment guidelines emerging?. Nephrol Dial Transplant 17 (2002) 1166-1169
11. Cosio F.G., Dillon J.J., Falkenhain M.E., et al. Racial differences in renal allograft survival: the role of systemic hypertension. Kidney Int 47 (1995) 1136-1141
12. Bolad I.A., Breen J., Rogers P., Partridge J., and Banner N.R. Prevalence and significance of renal artery stenosis and abdominal aortic atherosclerosis early after heart transplantation. Transplant Proc 34 (2002) 3236-3238
13. Wolf A., Trendelenburg C.F., ez-Fernandez C., et al. Cyclosporine A-induced oxidative stress in rat hepatocytes. J Pharmacol Exp Ther 280 (1997) 1328-1334
14. Fogo A., Hellings S.E., Inagami T., and Kon V. Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. Kidney Int 42 (1992) 770-774
15. Avdonin P.V., Cottet-Maire F., Afanasjeva G.V., et al. Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int 55 (1999) 2407-2414
16. Grieff M., Loertscher R., Shohaib S.A., and Stewart D.J. Cyclosporine-induced elevation in circulating endothelin-1 in patients with solid-organ transplants. Transplantation 56 (1993) 880-884
17. Navarro-Antolin J., Lopez-Munoz M.J., Klatt P., et al. Formation of peroxynitrite in vascular endothelial cells exposed to cyclosporine A. FASEB J 15 (2001) 1291-1293
18. Passauer J., Lassig G., Bussemaker E., Pistrosch F., and Gross P. Reduced endothelin-1- and nitric oxide-mediated arteriolar tone in hypertensive renal transplant recipients. Kidney Int 65 (2004) 1782-1789
19. Gerkens J.F. Cyclosporine treatment of normal rats produces a rise in blood pressure and decreased renal vascular responses to nerve stimulation, vasoconstrictors and endothelium-dependent dilators. J Pharmacol Exp Ther 250 (1989) 1105-1112
20. Roullet J.B., Xue H., McCarron D.A., Holcomb S., and Bennett W.M. Vascular mechanisms of cyclosporin-induced hypertension in the rat. J Clin Invest 93 (1994) 2244-2250
21. Somlyo A.P., and Somlyo A.V. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 522 Pt 2 (2000) 177-185
22. Cavarape A., Bauer J., Bartoli E., Endlich K., and Parekh N. Effects of angiotensin II, arginine vasopressin and tromboxane A2 in renal vascular bed: role of rho-kinase. Nephrol Dial Transplant 18 (2003) 1764-1769
23. Cavarape A., Endlich N., Assaloni R., et al. Rho-kinase inhibition blunts renal vasoconstriction induced by distinct signaling pathways in vivo. J Am Soc Nephrol 14 (2003) 37-45
24. Randriamboavonjy V., Busse R., and Fleming I. 20-HETE-induced contraction of small coronary arteries depends on the activation of Rho-kinase. Hypertension 41 (2003) 801-806
25. Schubert R., Kalentchuk V.U., and Krien U. Rho kinase inhibition partly weakens myogenic reactivity in rat small arteries by changing calcium sensitivity. Am J Physiol Heart Circ Physiol 283 (2002) H2288-H2295
26. Uehata M., Ishizaki T., Satoh H., et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389 (1997) 990-994
27. Saris J.J., van Dijk M.A., Kroon I., Schalekamp M.A., and Danser A.H. Functional importance of angiotensin-converting enzyme-dependent in situ angiotensin II generation in the human forearm. Hypertension 35 (2000) 764-768
28. Bussemaker E., Passauer J., Reimann D., et al. The vascular endothelin system is not overactive in normotensive hemodialysis patients. Kidney Int 62 (2002) 940-948
29. Passauer J., Bussemaker E., Range U., Plug M., and Gross P. Evidence in vivo showing increase of baseline nitric oxide generation and impairment of endothelium-dependent vasodilation in normotensive patients on chronic hemodialysis. J Am Soc Nephrol 11 (2000) 1726-1734
30. Bussemaker E., Pistrosch F., Forster S., et al. Rho kinase contributes to basal vascular tone in humans: role of endothelium-derived nitric oxide. Am J Physiol Heart Circ Physiol 293 (2007) H541-H547
31. Passauer J., Pistrosch F., Bussemaker E., et al. Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide. J Am Soc Nephrol 16 (2005) 959-965
32. Dawes M., Chowienczyk P.J., and Ritter J.M. Quantitative aspects of the inhibition by N(G)-monomethyl-L-arginine of responses to endothelium-dependent vasodilators in human forearm vasculature. Br J Pharmacol 134 (2001) 939-944
33. Masumoto A., Hirooka Y., Shimokawa H., et al. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 38 (2001) 1307-1310
34. Verhaar M.C., Strachan F.E., Newby D.E., et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97 (1998) 752-756
35. Ming X.F., Viswambharan H., Barandier C., et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 22 (2002) 8467-8477
36. Wolfrum S., Dendorfer A., Rikitake Y., et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 24 (2004) 1842-1847
37. Chitaley K., and Webb R.C. Nitric oxide induces dilation of rat aorta via inhibition of rho-kinase signalling. Hypertension 39 (2002) 438-442
38. Bolz S.S., Vogel L., Sollinger D., et al. Nitric oxide-induced decrease in calcium sensitivity of resistance arteries is attributable to activation of the myosin light chain phosphatase and antagonized by the RhoA/Rho kinase pathway. Circulation 107 (2003) 3081-3087
39. Teixeira C.E., Jin L., Ying Z., et al. Expression and functional role of the RhoA/Rho-kinase pathway in rat coeliac artery. Clin Exp Pharmacol Physiol 32 (2005) 817-824
40. Krotz F., Keller M., Derflinger S., et al. Mycophenolate acid inhibits endothelial NAD(P)H oxidase activity and superoxide formation by a Rac1-dependent mechanism. Hypertension 49 (2007) 201-208
41. Vetter M., Chen Z.J., Chang G.D., et al. Cyclosporin A disrupts bradykinin signaling through superoxide. Hypertension 41 (2003) 1136-1142
42. Yamakawa T., Tanaka S., Numaguchi K., et al. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension 35 (2000) 313-318
43. Higashi M., Shimokawa H., Hattori T., et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 93 (2003) 767-775
44. Gorlach A., Brandes R.P., Nguyen K., et al. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res 87 (2000) 26-32
45. Jung O., Schreiber J.G., Geiger H., et al. gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 109 (2004) 1795-1801
46. Passauer J., Bussemaker E., Lassig G., and Gross P. Kidney transplantation improves endothelium-dependent vasodilation in patients with endstage renal disease. Transplantation 75 (2003) 1907-1910
47. Morris S.T., McMurray J.J., Rodger R.S., Farmer R., and Jardine A.G. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int 57 (2000) 1100-1106
48. Ghanem H., van den Dorpel M.A., Weimar W., et al. Increased low density lipoprotein oxidation in stable kidney transplant recipients. Kidney Int 49 (1996) 488-493
49. Williams M.J., Sutherland W.H., McCormick M.P., et al. Vitamin C improves endothelial dysfunction in renal allograft recipients. Nephrol Dial Transplant 16 (2001) 1251-1255
50. Cofan F., Zambon D., Laguna J.C., et al. Pravastatin improves low-density lipoprotein oxidation in renal transplantation. Transplant Proc 34 (2002) 389-391